ReutersTiny stem cell companies close in on major heart disease goalsReutersThey are among the farthest along in the stem cell industry at a time when Wall Street investors have focused on potentially big payoffs from immune-system based cancer therapi… Continue reading
Reuters |
Tiny stem cell companies close in on major heart disease goals
Reuters Australia’s Mesoblast, with a market value of about $500 million, is attempting to alter advanced heart failure, a leading cause of hospitalizations and deaths and an enormous cost burden. They are among the farthest along in the stem cell industry at … |
PLoS Blogs (blog) |
My first time as an iGEM judge
PLoS Blogs (blog) The 2017 iGEM competition had over 5,000 student participants who all worked for months to design, build, and test their own synthetic biology projects. Once they’ve put all that work in, the teams travel from all over the world to Boston to present at … |